# US 2022/0031671 A1 · Treating sickle cell disease with a pyruvate kinase r activating compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031671 A1
- Document ID: US20220031671A1
- Status: Published application
- Kind: A1
- Application number: 17/275,741
- Filed: 2019-09-19
- Published: 2022-02-03
- Earliest claimed: 2018-09-19
- Assignees: Novo Nordisk Health Care AG
- Applicants: FORMA Therapeutics, Inc.
- Inventors: Anna ERICSSON; Neal GREEN; Gary GUSTAFSON; David R. LANCIA, Jr.; Gary MARSHALL; Lorna MITCHELL; David RICHARD; Zhongguo WANG; Sanjeev FORSYTH; Patrick F. KELLY; Madhu MONDAL; Maria RIBADENEIRA; Patricia SCHROEDER
- Web page: https://patentgrep.com/patent/US20220031671A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 7/06: Antianaemics
- C07D 487/04: Ortho-condensed systems
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

## Claims

### Claim 1

A pharmaceutical composition comprising Compound 1 and a pharmaceutically acceptable carrier:
for use in a method of treating a patient diagnosed with a sickle cell disease (SCD), the method comprising administering to the patient in need thereof a total of 25 mg-1,500 mg of Compound 1 per day.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the method comprises the administration of Compound 1 in a single dose once per day.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the method comprises the administration of Compound 1 in a divided dose each day.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1-3, wherein the composition is orally administered to the patient.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1-4, wherein the composition is formulated as an oral unit dosage form.

### Claim 6

A method of treating a patient diagnosed with a sickle cell disease (SCD), the method comprising orally administering to the patient in need thereof a total of 25 mg-1,500 mg per day of (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one in a pharmaceutical composition.

### Claim 7

A method of treating a patient diagnosed with a sickle cell disease (SCD), the method comprising orally administering to the patient in need thereof a total of 25 mg-1,500 mg of Compound 1 per day:
in a pharmaceutical composition comprising Compound 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 6, 7)

The method of any one of claims 6-7, wherein (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one is the only PKR Activating Compound in the pharmaceutical composition.

### Claim 9 (depends on 6, 7, 8)

The method of any one of claims 6-8, comprising the administration of Compound 1 in a single dose once per day.

### Claim 10 (depends on 6, 7, 8)

The method of any one of claims 6-8, comprising the administration of Compound 1 in a divided dose each day.

### Claim 11

A pharmaceutical composition comprising a PKR Activating Compound for use in a method of treating a patient diagnosed with sickle cell disease, comprising administering to the patient the PKR Activating Compound in an amount sufficient to reduce 2,3-DPG levels in the patient's red blood cells by at least 30% after 24 hours, wherein the PKR Activating Compound is a compound of Formula I:
or a pharmaceutically acceptable salt thereof, having an AC50 value of less than 1 μM using the Luminescence Assay described in Example 2.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the PKR Activating Compound is Compound 1:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The composition of claim 12, wherein Compound 1 is the only PKR Activating Compound administered to the patient.

### Claim 14 (depends on 11, 12, 13)

The composition of any one of claims 11-13, wherein the PKR Activating Compound is orally administered to the patient.

### Claim 15 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, wherein the PKR Activating Compound is administered once per day.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The composition of any one of claims 11-15, wherein the PKR Activating Compound is administered in an amount sufficient to reduce 2,3-DPG levels in the patient's red blood cells by at least 40% after 24 hours.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The composition of any one of claims 11-16, wherein the PKR Activating Compound is administered in a daily amount sufficient to increase the patient's ATP blood levels by at least 40% on day 14 of treatment.

### Claim 18 (depends on 11, 12, 13, 14, 15)

The composition of any one of claims 11-15, wherein the PKR Activating Compound is administered in an amount of 100 mg, 200 mg, 400 mg, 600 mg, 700 mg, 1100 mg, or 1500 mg per day.

### Claim 19 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, wherein the PKR Activating Compound is administered in an amount of 200 mg per day.

### Claim 20 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, wherein the PKR Activating Compound is orally administered in an amount of 200 mg per day once per day (QD).

### Claim 21 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, wherein the PKR Activating Compound is orally administered in an amount of 100 mg per day twice per day (BID).

### Claim 22 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, wherein the PKR Activating Compound is administered in an amount of 400 mg per day in a single or divided dose.

### Claim 23 (depends on 11)

The composition of claim 11, wherein the PKR Activating Compound is orally administered in an amount of 400 mg once per day (QD).

### Claim 24 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, wherein the PKR Activating Compound is orally administered in an amount of 200 mg twice per day (BID).

### Claim 25 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, wherein the PKR Activating Compound is administered in an amount of 700 mg per day in a single or divided dose.

### Claim 26 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, wherein the PKR Activating Compound is administered in an amount of 700 mg once per day (QD).

### Claim 27 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, wherein the PKR Activating Compound is orally administered in an amount of 350 mg twice per day (BID).
